Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease

Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis. In preclinical and retrospective clinical studies, use of ruxolitinib was shown to reduce graft-versus-host-disease (GVHD) in allograft...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Allison P., Brunstein, Claudio G., Holtan, Shernan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241238/
https://www.ncbi.nlm.nih.gov/pubmed/30519495
http://dx.doi.org/10.1155/2018/4539757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241238/
https://www.ncbi.nlm.nih.gov/pubmed/30519495
http://dx.doi.org/10.1155/2018/4539757

Ejemplares similares